U.S. markets closed
  • S&P 500

    3,719.04
    +71.75 (+1.97%)
     
  • Dow 30

    29,683.74
    +548.75 (+1.88%)
     
  • Nasdaq

    11,051.64
    +222.13 (+2.05%)
     
  • Russell 2000

    1,715.24
    +52.73 (+3.17%)
     
  • Crude Oil

    81.95
    +3.45 (+4.39%)
     
  • Gold

    1,667.90
    +31.70 (+1.94%)
     
  • Silver

    18.89
    +0.55 (+3.02%)
     
  • EUR/USD

    0.9738
    +0.0140 (+1.46%)
     
  • 10-Yr Bond

    3.7050
    -0.2590 (-6.53%)
     
  • GBP/USD

    1.0879
    +0.0148 (+1.38%)
     
  • USD/JPY

    144.1380
    -0.6530 (-0.45%)
     
  • BTC-USD

    19,553.94
    +528.88 (+2.78%)
     
  • CMC Crypto 200

    446.90
    +18.12 (+4.23%)
     
  • FTSE 100

    7,005.39
    +20.80 (+0.30%)
     
  • Nikkei 225

    26,173.98
    -397.89 (-1.50%)
     

Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program

·1 min read
  • RBC Capital Markets raised the price target on Alnylam Pharmaceuticals Inc (NASDAQ: ALNYfrom $225 to $250.

  • The analyst says that the company is confident that the recent APOLLO-B validates the therapeutic hypothesis.

  • Subgroup analysis at the Heart Failure Society of America (HFSA) next week will be limited by a small number, but ALNY sees an approvable drug.

  • Related: Alnylam Shares Detailed Patisiran Data From Rare Disease Study.

  • The base business continues to perform, and POC for Alzheimer's and gout is later this year.

  • RBC remains a buyer, noting one of the few commercially validated platforms in Biotech and prior transactions in the space.

  • Citi analyst says APOLLO-B data reported thus far suggests Onpattro is approvable for ATTR-CM and could potentially improve upon Pfizer Inc's (NYSE: PFE) tafamidis for cardiac outcomes.

  • Most importantly, data at HFSA might offer a glimpse into the potential of Onpattro's follow-up, Amvuttra, which has quarterly (potentially biannual) dosing and is likely to drive Alnylam's ATTR franchise.

  • Earlier today, the European Commission approved Amvuttra (vutrisiran) for hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.

  • Price Action: ALNY shares are down 2.32% at $210.98 on the last check Tuesday.

Latest Ratings for ALNY

Date

Firm

Action

From

To

Mar 2022

Citigroup

Initiates Coverage On

Buy

Feb 2022

Morgan Stanley

Maintains

Overweight

Feb 2022

SVB Leerink

Maintains

Market Perform

View More Analyst Ratings for ALNY

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.